XBIO
Xenetic Biosciences, Inc.
Biotechnology · Healthcare · United States
2.05
close · 2026-10-30
value
12
cheaper than peers12
quality
46
stronger fundamentals46
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.47× | 92 |
| price to book | 0.79× | 89 |
| cash flow yield, latest year | -47.6% | 19 |
| cash flow yield, 1 year ago | -58.7% | 14 |
| earnings yield, 2 years ago | -132.2% | 12 |
| earnings yield, latest year | -77.1% | 12 |
| cash flow yield, 3 years ago | -107.1% | 12 |
| cash flow yield, 2 years ago | -85.7% | 12 |
| earnings yield, 1 year ago | -125.4% | 11 |
| earnings yield, 3 years ago | -224.9% | 8 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -47.0% | 53 |
| operating margin | -147.1% | 49 |
| revenue growth | 12.0% | 44 |
3 of 4 measures available
Facts
| market cap | $5M |
| free cash flow | -$1.2M |
| employees | 2 |
| first trade | 2016-06-30 |
| next earnings | not reported |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
| diluted eps | -1.58 | -2.57 | -2.71 | -4.61 | not reported |
| free cash flow | -$2.3M | -$2.8M | -$4.1M | -$5.1M | not reported |
| net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | not reported |
| revenue | $3.0M | $2.5M | $2.5M | $1.7M | not reported |
| unusual items | not reported | not reported | not reported | not reported | $0 |